Could Polarean Imaging’s New VP Truly Drive Growth in Lung Imaging?

Highlights,Polarean Imaging focuses on advancements in functional lung imaging technology.,The company has set a higher revenue target, emphasizing gr...

AstraZeneca Unveils Ambitious $3.5 Billion Expansion Plan in the U.S...

Highlights:,Major U.S. Investment:,AstraZeneca to invest $3.5 billion in expanding its R&D and manufacturing capabilities across the U.S. by 2026.,Job...

GSK Downgraded as Analysts Cite Limited Near-Term Growth Prospects

Highlights:,Jefferies Downgrades GSK:,US bank Jefferies has reduced GSK's rating to 'hold,' citing a lack of upcoming catalysts for growth.,Concerns O...

AstraZeneca and Amgen Announce Positive Phase III Results for Tezspi...

Highlights:,Significant Symptom Relief,:,Tezspire,(,tezepelumab,) reduced nasal polyp size and congestion in patients with chronic rhinosinusitis.,New...

Indivior Engages with Activist Investor Oaktree Amid Calls for Board...

Highlights:,Oaktree Challenges Indivior Board,:,Activist investor Oaktree Capital seeks a major shake-up of Indivior’s board, citing concerns over str...

AstraZeneca Grapples with Market Uncertainty Following Value Decline

Highlights:,Significant Market Decline:,AstraZeneca has seen its market value drop by £50 billion since September, driven by concerns over its drug pi...

Positive Tezspire Trial Results Generate Enthusiasm at AstraZeneca

Highlights:,AstraZeneca announces positive results from the Phase III WAYPOINT trial for Tezspire (tezepelumab), a treatment for nasal polyps.,The tri...

Spire Healthcare Finalizes Strategic Share Buyback

Highlights:,Spire Healthcare Group PLC has completed the repurchase of 50,000 of its shares on the London Stock Exchange.,The shares were repurchased...

Roquefort Therapeutics Advances Growth Plans with Loan Note Conversi...

Highlights:,Roquefort Therapeutics PLC converts convertible loan notes into new shares.,The move is part of the company’s strategy to expand in immuno...

AstraZeneca Pledges Cooperation with China in Ongoing Anti-Corruptio...

Highlights:,Fraud Investigation Involving Executives:,AstraZeneca faces scrutiny as reports indicate involvement of senior China executives in a major...

Novo Nordisk Outpaces Expectations with Wegovy Sales Surge, Raises O...

Highlights:,Wegovy Sales Surge Past Forecasts:,Sales of Novo Nordisk's weight-loss drug, Wegovy, soared to $2.49 billion, surpassing analyst projectio...

Spire Healthcare Advances with Strategic Share Buyback

Highlights:,Spire Healthcare Group executes a share repurchase, acquiring 50,000 ordinary shares.,The repurchase reduces the total number of shares in...

Poolbeg Pharma’s POLB 001 Shows Promise in Reducing CRS Severity in...

Highlights:,Preventative Potential,:,POLB 001,demonstrated,success in reducing cytokine release syndrome (CRS) severity in preclinical models.,Clinica...

Roquefort Therapeutics Advances STAT-6 siRNA Research in Immunology...

Highlights:,Innovative Gene-Targeting Approach,:,Roquefort’s STAT-6 siRNA,programme,targets inflammation and immune response at the genetic level.,Pro...

AstraZeneca Loses £15bn in Value Over Weight Loss Drug Data, China F...

Highlights:,Early Data Disappoints on Weight Loss Drug:,AstraZeneca presented preliminary data for its GLP-1 weight loss drug, which fell short of som...

hVIVO PLC to Showcase Insights at Jefferies London Healthcare Confer...

Highlights:,hVIVO CEO, Yamin 'Mo' Khan, will present at the Jefferies Healthcare Conference in London on 19 November 2024 at 12:00pm GMT.,The Jefferie...

International Biotechnology Trust Reports Strong NAV Growth and Stra...

Highlights,Strong NAV Performance,: NAV rose 15.9%, outperforming the NASDAQ Biotechnology Reference Index’s 15.3% gain.,Strategic Investment Gains,:...

Spire Healthcare’s Buyback of Shares Successfully Completed

Highlights:,Spire Healthcare has repurchased 50,000 of its ordinary shares on the London Stock Exchange.,The share repurchase forms part of the compan...

Ondine Biomedical Launches £8.5 Million Fundraising Effort for U.S....

Highlights,Fundraising targets at least £8.5 million to fund a U.S. Phase 3 clinical trial for Ondine’s nasal photodisinfection technology.,A 36% incr...

Smith+Nephew Q3 2024 Trading Update: Revenue Growth Moderates Amid C...

Highlights,Q3 revenue rose 4% YoY to $1,412 million, with strong growth outside China.,Orthopaedics, Sports Medicine, and Advanced Wound Management se...